Evidence map›Paper›PMID 34523337›Full record

ArticleMolecular pharmaceutics2021

Fluorine-18 Labeling of the MDM2 Inhibitor RG7388 for PET Imaging: Chemistry and Preliminary Evaluation.

Zhengyuan Zhou, Michael R Zalutsky, Satish K Chitneni

Open access · greenAbstract read
In one paragraph

Article in Molecular pharmaceutics, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.4field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Chemical Probes and Activity-Based Protein Profiling for Cancer Research.International journal of molecular sciences · 2022
    Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Zhengyuan ZhouDepartment of Radiology, Duke University Medical Center, Durham, North Carolina 27710, United States.
Michael R ZalutskyDepartment of Radiology, Duke University Medical Center, Durham, North Carolina 27710, United States.
Satish K ChitneniDepartment of Radiology, Duke University Medical Center, Durham, North Carolina 27710, United States.ORCID 0000-0003-1183-2286
Duke Medical Center · US

Funding

Flourine-18 labeled MDM2 antagonists for PET imagingR21CA241823 · NCI · DUKE UNIVERSITY · PI CHITNENI, SATISH K. · 2020 to 2021
$414k
NCI NIH HHS R21 CA241823
6 · The paper itself

Abstract

RG7388 (Idasanutlin) is a potent inhibitor of oncoprotein murine double minute 2 (MDM2). Herein we investigated the feasibility of developing

Indexed as

Fluorine RadioisotopesAnimalsAntineoplastic AgentsBinding, CompetitiveHep G2 CellsHumansMaleMiceMice, NudeNeoplasm Transplantationpara-AminobenzoatesPositron-Emission TomographyProto-Oncogene Proteins c-mdm2PyrrolidinesAntineoplastic AgentsFluorine-18Fluorine Radioisotopespara-AminobenzoatesProto-Oncogene Proteins c-mdm2PyrrolidinesRG7388AMG232fluorine-18MDM2PETRG7388SJSA-1

Identifiers

PMID34523337
PMCPMC8775362
OpenAlexW3199683821

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.